HIV Pharm Flashcards

(68 cards)

1
Q

When on tenofovir, what test do you need to have and how often?

A

urinalysis q 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What test do you need when giving a patient abacavir?

A

HLA-B 5701 test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What tests do you need when giving a patient CCR5 blocker (ex: maraviroc)?

A

tropism testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is ART?

A

antiretroviral therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the fxn of ART?

A

reduce HIV-related morbid/mort at ALL stages of infection

reduced HIV transmission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How does ART work?

A

suppresses plasma RNA viremia–> delays or prevents mutations, improves CD4 numbers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How does ART in HIV therapy decrease cardiovascular and end-organ damage?

A

decreases inflammation and immune activation thought to contribute to them

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Can eradication of HIV be achieved with antiretrovirals?

A

no

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What can occur with abrupt ART discontinuation?

A

rebound viremia
worsening immune fxn
increased morb/mort

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe current ARV regimens

A

for viral suppression: combo of 3 active drugs from more than 2 drug classes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the predictors of virologic success in HIV tmt

A

low baseline viremia

high potency of ARV regimen

tolerability of regimen

convenience of regimen

excellect adherence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How fast does viral load reduction occur with ART

A

12-24 weeks, viral load is below limits of assay detection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are targets of HIV therapy?

A

nucleoside reverse transcriptase -

non-nucleoside reverse transcriptase -

integrase strand transfer - (inhibits integration)

HIV fusion - (inhibits attachment and fusion)

CCR5 - (inhibits CD4 and chemokine receptors used for attachment)

protease - (inhibits maturation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the backbone of ART?

A

2 NRTIs that target different bases are combined

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How do NRTIs work?

A

enter cell and phosphorlyated

compete for base pairs in the growing viral DNA strand, leads to termination of DNA production from RNA (lack 3’OH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What ARV drug prevents infection of susceptible cells but DOES NOT eradicate virus from cells that are already infected?

A

NRTIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What base pair does the NRTI AZT (zidovudine) compete with?

A

thymidine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What base pair does the NRTI emtricitabine compete with?

A

cytidine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What base pair does the NRTI lamivudine compete with?

A

cytidine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What base pair does the NRTI abacavir compete with?

A

Guanosine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What base pair does the NRTI tenofovir compete with?

A

adenosine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Describe selective toxicity of NRTIs

A

need to inhibit HIV reverse transcriptase without disrupting host cell DNA poly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What NRTIs would you use to not disrupt mitochondrial DNA polymerase y (d/t drugs having low affinity for DNA poly y)?

A

emtricitabine

lamivudine

abacavir

tenofovir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Describe toxicities a/q NRTIs

A

lactic acidosis syndrome (d/t mito tox)

peripheral neuropathy (d/t mito tox)

pancreatitis (d/t mito tox)

anemia

myopathy

*****risks much lower now d/t use of drugs that don’t affect mito (tenofovir, abacavir, lamivudine, emtricitabine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
What are toxicities of AZT/zidovudine?
bone marrow suppression skeletal muscle myopathy hepatic steatosis
26
Which NRTI was the first ARV discovered, competes with thymidine and is the only NRTI available IV?
AZT (zidovudine)
27
Which NRTI competes with thymidine but is rarely used because of toxicities such as fat wasting (lipodystrophy)?
stavudine (d4T) also peripheral neuropathy, lactic acidosis, hepatic steatosis
28
Which NRTI competes with cytosine, terminates elongation of DNA, has a long intracellular half-life, low barrier to resistance, active againts HBV, co-formulated with tenofovir (superior combo), and is excreted unchanged in urine?
emtricitabine (FTC)
29
What are toxicities a/w emtricitabine (FTC)?
ONE OF THE LEAST TOXIC ARV prolonged use--> hyperpigmentation of palms and soles in AA
30
What NRTI mimics emtricitabine but can be used as dual treatment with doltegravir for treatment in naive patients with low HIV numbers in plasma?
lamivudine (3TC)
31
What NRTI is the only guanine analog, NOT effective against HBV, not a CYP substrate, half life of 21 hours and shouldn't be given to pt with HLA B 5701 genotype (-->fatal hypersensitivity)?
ABC (abacavir)
32
What are toxicities a/w ABC (abacavir)?
potentially fatal hypersensitivity syndrome d/t HLA B 5701 genotype avoid in pts with CAD d/t a/w hyperlipidemia
33
What drug is a nuleoTIDE RTI, competes with adenosine, is approved for HBV, has a long half-life so can do 1x day dosing and is unchanged in urine?
TDF (tenofovir disoproxil fumarate)
34
What toxicities are a/w TDF?
nephrotoxicity with acute tubular necrosis--> Fanconi syndrome decreased bone mineral density
35
What is didanosine?
adenosine analong that is toxic d/t mito effects
36
What drug is a nuleoTIDE RTI, competes with adenosine, is approved for HBV, has a long half-life so can do 1x day dosing, is unchanged in urine and is well tolerated?
tenofovir alafenamine (TAF) transported differently c/w TDF (low dose but high intracellular concentrations)
37
What NRTI combo is used and superior to other combos?
emtricitabine and tenofovir
38
Are emtricitabine and lamivudine combined?
NO because they are both cytosine analogs
39
Are TAF and TDF combined?
no, both prodrugs with active tenofovir
40
What NRTI combo is used in naive patients with HIV?
lamivudine combined with INSTI dolutegravir
41
What active agents are recommended for treatment in naive HIV patients?
integrase strand transfer inhibitors (INSTI)
42
What do all INSTI drugs end in?
-gravir
43
What INSTI prevents formation of covalent bonds between viral and host DNA, generally well tolerated and is excellent target (DNA of humans doesn't undergo excision/reintegration)?
raltegravir
44
What INSTI blocks chromosomal integration of viral DNA, can develop resistence (high genetic barrier though) and should be avoided in pregnancy d/t neural tube defects?
dolutegravir
45
What INSTI is metabolized by CYP3A4 and needs to be boosted?
elvitegravir (combined with cobicistat)
46
What INSTI has similar resistance c/w dolutegravir but is only available as fixed-dose single tablet?
bictegravir
47
What are second line ART active agents?
protease inhibitors --> prevent cleavage of polypeptide and subsequent maturation of virion
48
How do protease inhibitors work?
competitively inhibit virus aspartyl protease (homodimer) --> human protease are monomers so not affected prevent cleavage of HIV gag and pol precursors that are needed to make reverse transcriptase, protease and integrase (mature)
49
Do PIs penetrate CSF?
no, highly protein bound
50
How do PIs affect CYP3A4?
inhibit metabolism of other drugs --> ritonavir used to boost other agents with low dose *****all substrates for P-glycoprotein
51
What is unique about indinavir?
early PI no longer recommended, but unique d/t crystaluria/renal stones
52
What drug was the first PI but is no longer widely used d/t pill burden?
saquinavir
53
What PI is a sulfa drug and can cause rashes?
darunavir
54
What PI causes unconjugated hyperbilirubinemia not associated with hepatitis?
atazanavir
55
What PI often works after failure of other PI-containing regiments and was boosted with ritonavir?
lopinavir --> now replaced with darunavir and azatanavir
56
What are the CYP3A4 inhibitors that boost PIs?
ritonavir cobicistat
57
What are third line active agents in ART?
Non-nucleoside reverse transcriptase inhibitors (NNRTI)
58
How do NNRTIs work?
only active against HIV 1 ---> HIV 2 resistant non-competitive antagonist to reverse transcriptase-->denatures it by binding to p66
59
What can happen with a single aa substitution in a pocket of NNRTIs?
resistance ex: single exposure to nevirapine causes resistance, must be combined with other drugs to prevent rapid resistance
60
What NNRTI was first approved for once daily dosing, is co-formulated with emtricitabine and tenofovir, should not be added to failing regimen and has CNS toxicity?
efavirenz was considered teratogenic but not anymore
61
What NNRTI is unique in that it still works after mutations that disrupt activity of other NNRTIs?
etravirine
62
What is the newest NNRTI that is best in class that has novel resistance mutations?
doravirine
63
What NNRTI is used with HIV-1 naive patients?
rilpivirine also not susceptible to malfunction with mutations
64
How do HIV fusion inhibitors work
add T20 peptides, prevent conformation change and fusion of virus with host
65
What drug is a 36aa peptide that inhibits viral infection via blocking fusion, not active against HIV-2, and must be given parenterally?
enfuvirtide (T-20) hella expensive and not used very often
66
What drug binds to CCR5 co-receptor and blocks entry into cells, NOT active against CXCR4 viruses, is a CYP3A4 substrate and generally well tolerated?
maraviroc not rec as initial therapy, seldom used
67
Maintaining less than 200 copies/mL of plasma HIV RNA...
prevents sexual transmission of HIV if first starting ART, wait 6 months or use other protection
68
What drug can cause neural tube defects?
dolutegravir